|
Plan to roll out vaccines in China多国启动大规模新冠疫苗接种导读:疫苗来了!为遏制疫情,全球多国启动大规模新冠疫苗接种计划。12月中旬,英国和美国先后开启了大规模新冠疫苗接种。随后,中国也宣布了一系列措施,“部分重点人群”将于冬春季率先接种疫苗。
Many countries have planned to release vaccines to combat the COVID-19. XINHUA After months of waiting for an effective vaccine to combat the pandemic, some countries are kicking off mass COVID-19 vaccinations, bringing hope to people in hard-hit regions. On Dec 8, the United Kingdom started its large-scale COVID-19 vaccination, with the vaccine developed by the United States pharmaceutical company Pfizer and its German development partner BioNTech. On Dec 14, the US also started its COVID-19 vaccine rollout nationwide, as the death toll of the pandemic in the country topped 300,000, Xinhua reported. China will also start getting some key groups vaccinated over the winter, Zeng Yixin, deputy head of the National Health Commission (NHC) said at a press conference on Dec 19. People who engaged in the cold-chain industry, or other high-risk groups who work in healthcare, seafood markets and public transportation, will receive the vaccines first. The vaccination program will also cover those who plan to work or study in countries and regions with higher risks of exposure to the virus, according to the NHC. This is the first step in China’s COVID-19 vaccination plan. It will help relieve the pressure in preventing and controlling imported COVID-19 cases and also lower the risk of outbreaks. Next, with COVID-19 vaccines officially approved to enter the market and the output of vaccines improving steadily, China will put more vaccines into use. Senior citizens, people with underlying diseases and the general public will then receive vaccines. According to Xinhua, China’s COVID-19 vaccine development has entered the “final sprint”, with five vaccines undergoing phase-3 clinical trials. Over 1 million people at high risk of exposure have been given emergency vaccinations since July. Of those cases, no serious adverse effects have been reported so far, said Zheng Zhongwei from the NHC. According to a report published on the Science magazine website, a COVID-19 vaccine developed by China National Pharmaceutical Group proved to have “outstanding efficacy data”. An analysis shows the vaccine to have 100 percent effectiveness in preventing moderate and severe cases of COVID-19 and no serious safety concerns, Xinhua reported. As for those who are not among the first groups to receive vaccines, officials at the NHC said there’s no need to be anxious. “We advise the public to maintain personal hygiene and protection, including wearing masks, washing hands and practicing social distancing. These measures prove to be effective protection against the virus,” said Cui Gang, a senior official with the commission.
21英语网站版权说明 (Translator & Editor: Wang Yue (Intern) AND Wang Xingwei)
|
|
主办
|
中报二十一世纪(北京)传媒科技有限公司版权所有,未经书面授权,禁止转载或建立镜像。 主办单位:中国日报社 Copyright by 21st Century English Education Media All Rights Reserved 版权所有 复制必究 网站信息网络传播视听节目许可证0108263 京ICP备2024066071号-1 京公网安备 11010502033664号 |